CRX.L Regulatory News (CRX)

26 May 2006 07:01

Cyprotex PLC26 May 2006 Press Release 26 May 2006 CYPROTEX PLC ("Cyprotex" or "the Group") Cyprotex expands further in to the United States with the appointment of Global Head of Business Development Cyprotex PLC (LSE: CRX), the drug discovery technology and information company,is pleased to announce its further expansion in to the United States. MitchellWinfree has been appointed the senior role of Global Head of BusinessDevelopment. His role is further complemented by the additional appointment ofa Director of West Coast Business Development. Both will concentrate oncapturing North American sales opportunities. The US is seen to offer a great wealth of opportunities for Cyprotex in terms ofkey partners, collaborations and customers. With as much as 60% of the earlystage global drug development concentrated in North America, an abundance ofsmall and medium-sized biotechs / Contract Research Organisations (CRO's) andgenerally greater propensity toward outsourcing services such as high-throughputADME/Tox screening, this territory has become a principal focus. Mitchell Winfree becomes Global Head of Business Development and bringsinternational experience in the pharmaceutical and biotechnology industry,having held senior positions at both Absorption Systems LP, a privately held CROworking with Pharmaceuticals and Biotech partners, and PPD, Inc (DNA Sciences,Inc) an applied genetics company focused on the discovery and commercializationof DNA based diagnostic tests Cyprotex has also appointed an experienced Director of West Coast BusinessDevelopment, with a view to echoing the success of last year's similarappointment on the East Coast. Commenting on these appointments, Robert Morrisson Atwater, CEO of Cyprotex,said: 'We welcome the new appointments into the Cyprotex Group. Bothindividuals have significant experience and innovative flair, and will play asubstantial role in driving forward sales as the Company enters into an excitingphase of growth and development." - Ends - For further information: Cyprotex PLCRobert Morrisson Atwater Tel: +44 (0) 1625 505 100Chairman & Chief Executive Officerir@cyprotex.com www.cyprotex.com Code Securities LimitedChris Collins, Corporate Finance Tel: +44 (0) 20 7776 1200cic@codesecurities.com www.codesecurities.com Media enquiries: AbchurchHeather Salmond / Georgina Bonham Tel: +44 (0) 20 7398 7700heather.salmond@abchurch-group.com www.abchurch-group.com Notes for Editors: Cyprotex plc - www.cyprotex.com Cyprotex is a specialist provider of experimental and computational capabilitiesto support ADME (Absorption/Distribution/Metabolism/Excretion), toxicity andpharmacokinetics assessment for drug discovery partners. Its core productsinclude the Cloe ScreenTM in vitro ADME/toxicity service, and Cloe PKTM - apharmacokinetics prediction system which integrates core ADME andphysicochemical compound data to predict compound levels in plasma and majororgans in the body. This unique combination of technologies is aimed atimproving pharmaceutical productivity by improving the quality of compoundlibraries and drug candidates progressing through the drug pipeline. Cyprotexis based in the UK and is listed on the London Stock Exchange (CRX). This information is provided by RNS The company news service from the London Stock Exchange